Prognostic Value of Serum Biomarkers in Patients with Idiopathic Pulmonary Fibrosis in Relation to Disease Progression

Overview

Journal J Pers Med

Date 2023 Sep 28

PMID 37763075

Authors

Kalliopi Domvri

Ioannis Organtzis

Apostolos Apostolopoulos

Evangelia Fouka

Theodoros Kontakiotis

Despoina Papakosta

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this present study was to determine serum biomarker levels and their correlation with respiratory function and the clinical course of patients with idiopathic pulmonary fibrosis (IPF).

Materials And Methods: This study included 72 IPF patients, according to the ATS/ERS criteria, in whom antifibrotic treatment was initiated. Blood samples were taken, and serum biomarkers, such as KL-6, SP-D, CCL18, CXCL13, VEGF-A, IL-8, IGFBP-1, IGFBP-2, IGFBP-7 and ICAM-1 were measured using ELISA methodology. Pulmonary function tests (FVC, TLC, DLCO-% pred) were determined at baseline and after 12 and 24 months and analyzed in correlation with the biomarkers.

Results: The majority of patients (mean age 72 ± 6 years) were men (83%). The FVC and DLCO values at the 12-month follow-up were found to be statistically decreased in deceased patients ( < 0.05). The SP-D ( < 0.001) and the IGFBP-1 ( = 0.021) levels were found to be increased at the 1-year follow-up in deceased patients, and similarly, the SP-D ( = 0.005) and ICAM-1 ( = 0.043) levels at the 2-year follow-up. A chi-square test revealed that 70% of the category IV GAP index was found with cut-off elevated levels of a biomarker combination (KL-6, SP-D, VEGF-A) from the ROC curve analysis ( < 0.05).

Conclusion: This study provides evidence, for the first time in a Greek population, of the possibility of using a combination of KL-6, SP-D, and VEGF-A serum levels along with the GAP index.

Citing Articles

Serum surfactant protein D as a significant biomarker for predicting occurrence, progression, acute exacerbation, and mortality in interstitial lung disease: a systematic review and meta-analysis.

He X, Ji J, Zheng D, Luo Z, Luo L, Guo L Front Immunol. 2025; 16:1450798.

PMID: 40028331 PMC: 11868069. DOI: 10.3389/fimmu.2025.1450798.

Predictors of relapse of polymyositis/dermatomyositis associated interstitial lung disease.

Kishaba T, Yano H, Itagane M, Sudo K, Nagano H, Kinjo M J Thorac Dis. 2024; 16(7):4229-4237.

PMID: 39144313 PMC: 11320281. DOI: 10.21037/jtd-23-1736.

Role of BAL and Serum Krebs von den Lungen-6 (KL-6) in Patients with Pulmonary Fibrosis.

Soccio P, Moriondo G, DAlessandro M, Scioscia G, Bergantini L, Gangi S Biomedicines. 2024; 12(2).

PMID: 38397871 PMC: 10886706. DOI: 10.3390/biomedicines12020269.

Development of a Novel Biomarker for the Progression of Idiopathic Pulmonary Fibrosis.

Yeo H, Ha M, Shin D, Lee H, Kim Y, Cho W Int J Mol Sci. 2024; 25(1).

PMID: 38203769 PMC: 10779374. DOI: 10.3390/ijms25010599.

Efficacy and Safety of Hydrogen Therapy in Patients with Early-Stage Interstitial Lung Disease: A Single-Center, Randomized, Parallel-Group Controlled Trial.

Tang C, Wang L, Chen Z, Yang J, Gao H, Guan C Ther Clin Risk Manag. 2023; 19:1051-1061.

PMID: 38107500 PMC: 10723077. DOI: 10.2147/TCRM.S438044.

References

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

Hamano Y, Kida H, Ihara S, Murakami A, Yanagawa M, Ueda K . Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. Sci Rep. 2017; 7:43201. PMC: 5322336. DOI: 10.1038/srep43201. View

Ryerson C, Vittinghoff E, Ley B, Lee J, Mooney J, Jones K . Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2013; 145(4):723-728. DOI: 10.1378/chest.13-1474. View

Chadelat K, Boule M, Corroyer S, Fauroux B, Delaisi B, Tournier G . Expression of insulin-like growth factors and their binding proteins by bronchoalveolar cells from children with and without interstitial lung disease. Eur Respir J. 1998; 11(6):1329-36. DOI: 10.1183/09031936.98.11061329. View

Barochia A, Kaler M, Weir N, Gordon E, Figueroa D, Yao X . Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis. Eur Respir J. 2021; 58(6). PMC: 9389624. DOI: 10.1183/13993003.04053-2020. View

Papiris S, Kannengiesser C, Borie R, Kolilekas L, Kallieri M, Apollonatou V . Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective. Diagnostics (Basel). 2022; 12(12). PMC: 9777433. DOI: 10.3390/diagnostics12122928. View

Guiot J, Bondue B, Henket M, Corhay J, Louis R . Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC Pulm Med. 2016; 16(1):86. PMC: 4877734. DOI: 10.1186/s12890-016-0249-6. View

Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584. View

Li Y, He Y, Chen S, Wang Q, Yang Y, Shen D . S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis. Front Immunol. 2022; 13:810338. PMC: 8854978. DOI: 10.3389/fimmu.2022.810338. View

10.

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Ryerson C, Lederer D . Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5):e44-e68. DOI: 10.1164/rccm.201807-1255ST. View

11.

Munchel J, Shea B . Diagnosis and Management of Idiopathic Pulmonary Fibrosis. R I Med J (2013). 2021; 104(7):26-29. View

12.

Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K . Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med. 2014; 108(7):1031-9. DOI: 10.1016/j.rmed.2014.04.009. View

13.

Ishikawa N, Hattori N, Yokoyama A, Kohno N . Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012; 50(1):3-13. DOI: 10.1016/j.resinv.2012.02.001. View

14.

Wakamatsu K, Nagata N, Kumazoe H, Oda K, Ishimoto H, Yoshimi M . Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig. 2016; 55(1):16-23. DOI: 10.1016/j.resinv.2016.09.003. View

15.

Papiris S, Tomos I, Karakatsani A, Spathis A, Korbila I, Analitis A . High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations. Cytokine. 2017; 102:168-172. DOI: 10.1016/j.cyto.2017.08.019. View

16.

Magro C, Allen J, Pope-Harman A, Waldman W, Moh P, Rothrauff S . The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol. 2003; 119(4):556-67. DOI: 10.1309/0B06-Y93E-GE6T-Q36Y. View

17.

Lacedonia D, De Pace C, Rea G, Capitelli L, Gallo C, Scioscia G . Machine Learning and BMI Improve the Prognostic Value of GAP Index in Treated IPF Patients. Bioengineering (Basel). 2023; 10(2). PMC: 9952368. DOI: 10.3390/bioengineering10020251. View

18.

Inchingolo R, Varone F, Sgalla G, Richeldi L . Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2018; 13(1):39-51. DOI: 10.1080/17476348.2019.1553620. View

19.

Ley B, Bradford W, Weycker D, Vittinghoff E, du Bois R, Collard H . Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45(5):1374-81. DOI: 10.1183/09031936.00146314. View

20.

Bi Y, Rekic D, Paterniti M, Chen J, Marathe A, Chowdhury B . A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients. J Pharmacokinet Pharmacodyn. 2020; 48(1):55-67. DOI: 10.1007/s10928-020-09718-9. View